Journal
CRITICAL CARE MEDICINE
Volume 28, Issue 9, Pages S34-S37Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00003246-200009001-00008
Keywords
sepsis; septic shock; antithrombin III; coagulation; anticoagulation
Categories
Ask authors/readers for more resources
Objective: To review the preclinical evidence that provides the therapeutic rationale for antithrombin as a novel treatment for human sepsis. Data Sources: A summary of published medical literature from MEDLINE search files and other reviews published about antithrombin use in sepsis. Data Summary: Antithrombin has a variety of anti-inflammatory properties in addition to its functions as an endogenous anticoagulant that appear to have an important therapeutic role in the prevention of microvascular dysfunction and multiple organ injury in sepsis. Appropriate timing and dosing of antithrombin III is critical to realize its full therapeutic potential as an anti-sepsis therapy. Conclusions: Antithrombin is a potent inhibitor of thrombin-mediated vascular injury in the microcirculation in severe sepsis. This endogenous anticoagulant is rapidly depleted in the early phases of sepsis as a result of decreased synthesis, increased destruction, and enhanced clearance by thrombin-antithrombin complex formation. The therapeutic efficacy of antithrombin in experimental sepsis is readily demonstrable in numerous animal systems. Appropriately defined patient populations with early onset severe sepsis and/or septic shock may benefit from antithrombin therapy if it is administered in adequate doses at the optimal time interval.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available